{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.23","value":"22.58"},{"groupId":"OG001","spread":"4.61","value":"22.76"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"187"},{"groupId":"OG001","value":"187"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.49","value":"-1.56"},{"groupId":"OG001","spread":"4.06","value":"-0.69"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"156"},{"groupId":"OG001","value":"154"}],"units":"Participants"}],"title":"CFB at Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.21","value":"-6.80"},{"groupId":"OG001","spread":"2.83","value":"-3.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"CFB at Cycle 4 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.06","value":"-1.82"},{"groupId":"OG001","spread":"4.16","value":"-0.72"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"145"}],"units":"Participants"}],"title":"CFB at Cycle 5 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.14","value":"-1.00"},{"groupId":"OG001","spread":"4.62","value":"-0.61"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"142"}],"units":"Participants"}],"title":"CFB at End of Induction Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.14","value":"0.62"},{"groupId":"OG001","spread":"4.45","value":"0.58"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"133"}],"units":"Participants"}],"title":"CFB at Follow-up Month 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.58","value":"0.53"},{"groupId":"OG001","spread":"4.47","value":"0.88"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"121"}],"units":"Participants"}],"title":"CFB at Follow-up Month 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.74","value":"0.29"},{"groupId":"OG001","spread":"3.82","value":"0.91"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"112"}],"units":"Participants"}],"title":"CFB at Follow-up Month 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.53","value":"-0.01"},{"groupId":"OG001","spread":"3.96","value":"0.87"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"104"}],"units":"Participants"}],"title":"CFB at Follow-up Month 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.16","value":"0.06"},{"groupId":"OG001","spread":"3.81","value":"0.56"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"91"}],"units":"Participants"}],"title":"CFB at Follow-up Month 10"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.02","value":"0.26"},{"groupId":"OG001","spread":"4.24","value":"0.74"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"90"}],"units":"Participants"}],"title":"CFB at Follow-up Month 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.14","value":"0.03"},{"groupId":"OG001","spread":"3.94","value":"0.71"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"85"}],"units":"Participants"}],"title":"CFB at Follow-up Month 14"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.49","value":"-0.10"},{"groupId":"OG001","spread":"3.68","value":"1.31"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"82"}],"units":"Participants"}],"title":"CFB at Follow-up Month 16"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.64","value":"-0.22"},{"groupId":"OG001","spread":"3.99","value":"0.92"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"76"}],"units":"Participants"}],"title":"CFB at Follow-up Month 18"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.70","value":"-0.36"},{"groupId":"OG001","spread":"3.69","value":"0.74"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"73"}],"units":"Participants"}],"title":"CFB at Follow-up Month 20"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.93","value":"-0.25"},{"groupId":"OG001","spread":"4.47","value":"0.40"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"71"}],"units":"Participants"}],"title":"CFB at Follow-up Month 22"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.16","value":"-0.77"},{"groupId":"OG001","spread":"4.42","value":"0.52"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"68"}],"units":"Participants"}],"title":"CFB at Follow-up Month 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.17","value":"0.16"},{"groupId":"OG001","spread":"4.47","value":"0.22"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"106"}],"units":"Participants"}],"title":"CFB at Final Follow-up"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.48","value":"0.36"},{"groupId":"OG001","spread":"4.71","value":"0.57"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"60"}],"units":"Participants"}],"title":"CFB at Extension Follow-up Month 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.54","value":"0.80"},{"groupId":"OG001","spread":"4.98","value":"1.19"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"46"}],"units":"Participants"}],"title":"CFB at Extension Follow-up Month 18"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.96","value":"1.53"},{"groupId":"OG001","spread":"5.26","value":"0.56"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"39"}],"units":"Participants"}],"title":"CFB at Extension Follow-up Month 24"}],"denoms":[{"counts":[{"groupId":"OG000","value":"187"},{"groupId":"OG001","value":"187"}],"units":"Participants"}],"description":"The FACT-Lym measures 5 sub-scales which includes 42 items; responses to each item range from 0, \"Not at all\" to 4, \"Very much\". Total score ranges from 0-168. Physical Well-being sub-scale includes 7 items measured on 0-4 point scale. The total score for physical well-being sub-scale is sum of each 7 items (range: 0-28). Higher scores indicate a better participant-reported outcome (PRO)/quality of life (QoL). In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction) and extension follow-up months represents months after end of 2 years normal follow-up (e.g. extension follow-up Month 6 is 6 months after end of normal 2 year follow-up).","dispersionType":"Standard Deviation","groups":[{"description":"Participants received Bendamustine 120 mg/m\\^2 IV infusion on Days 1 and 2 of each 28-day cycle for up to six cycles.","id":"OG000","title":"Bendamustine Alone"},{"description":"Induction phase: Participants received Bendamustine 90 mg/m\\^2 IV on Days 2 and 3 of Cycle 1 and on Days 1 and 2 of Cycles 2-6 (28-day cycles) for the first 10 participants and on Days 1 and 2 of each 28-day cycle for Cycles 1-6 for remaining participants. Participants also received obinutuzumab 1000 mg IV infusion on Days 1, 8, and 15 of Cycle 1; Day 1 of Cycles 2-6. Maintenance phase: Participants with CR, PR or SD then received obinutuzumab 1000 mg IV infusion every 2 months until disease progression or for up to 2 years (whichever occurred first).","id":"OG001","title":"Obinutuzumab + Bendamustine"}],"paramType":"MEAN","populationDescription":"ITT population. Here, number of participants analyzed signified those participants who were evaluable for this outcome and \"n\" signified those participants who were evaluable for a specified time point.","reportingStatus":"POSTED","timeFrame":"Baseline, Day 1 of Cycles 3, 4, 5, End of induction treatment (up to Month 6); Follow-up Months 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, Final Follow-up (up to 2 years after end of induction); Extension follow-up Months 6, 18 and 24","title":"Change From Baseline (CFB) in Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym)-Physical Well Being Sub-scale Score","type":"SECONDARY","unitOfMeasure":"units on a scale"}